The emergence of the COVID-19 JN.1 variant has garnered global attention due to its increasing prevalence across multiple regions. First identified in August 2023, JN.1 is a descendant of the Omicron subvariant BA.2.86. Common clinical symptoms associated with JN.1 infection include sore throat, fever, dry cough, nausea, and vomiting. Although the World Health Organization has classified JN.1 as a Variant of Interest, it currently poses a low global health risk. Nonetheless, its enhanced transmissibility, particularly in cold and dry climates, warrants close monitoring. This review provides an in-depth analysis of JN.1's biological profile, epidemiological trends, transmissibility, immune-evasion capabilities, and vaccine responsiveness. A detailed literature review was conducted between January 2023 and August 2024, focusing on recent research regarding the spread and clinical implications of JN.1. Current evidence indicates that the L4555 spike protein mutation is the primary factor contributing to JN.1's increased infectivity and stronger immune evasion compared to earlier variants. The variant demonstrated a steady rise in transmission rates from November 2023 to March 2024. Despite these challenges, existing vaccines continue to offer substantial protection against the severe illness associated with this variant. Antiviral medications such as Lagevrio, Veklury, and Paxlovid also remain effective against JN.1. Continuous surveillance approaches, including digital tracking systems, wastewater monitoring, and genomic sequencing, are essential for the early detection and control of JN.1.
Rani et al. (2026) studied this question.